NASDAQ: RDUSRadius Recycling Stock
$28.03-0.22 (-0.78%)
Updated Sep 20, 2023
RDUS Price
$28.03
Fair Value Price
$28.85
Market Cap
$771.14M
52 Week Low
$25.96
52 Week High
$36.64
P/E
73.76x
P/B
0.82x
P/S
0.25x
PEG
N/A
Dividend Yield
2.68%
Revenue
$3.06B
Earnings
$10.38M
Gross Margin
9.9%
Operating Margin
0.94%
Profit Margin
0.3%
Debt to Equity
0.99
Operating Cash Flow
$184M
Beta
1.28
Next Earnings
Oct 23, 2023
Ex-Dividend
N/A
Next Dividend
N/A
RDUS Overview
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.
Zen Score
–
Industry Average (36)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RDUS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RDUS ($28.03) is undervalued by 2.83% relative to our estimate of its Fair Value price of $28.85 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
RDUS ($28.03) is not significantly undervalued (2.83%) relative to our estimate of its Fair Value price of $28.85 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RDUS was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more RDUS due diligence checks available for Premium users.
Be the first to know about important RDUS news, forecast changes, insider trades & much more!
RDUS News
Valuation
RDUS fair value
Fair Value of RDUS stock based on Discounted Cash Flow (DCF)
Price
$28.03
Fair Value
$28.85
Undervalued by
2.83%
RDUS ($28.03) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RDUS ($28.03) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RDUS was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RDUS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
73.76x
Industry
13.47x
Market
14.54x
RDUS is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
RDUS is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
RDUS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.82x
Industry
0.96x
RDUS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RDUS's financial health
Profit margin
Revenue
$809.6M
Net Income
$13.5M
Profit Margin
1.7%
RDUS's Earnings (EBIT) of $28.86M... subscribe to Premium to read more.
Interest Coverage Financials
RDUS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.9B
Liabilities
$926.8M
Debt to equity
0.99
RDUS's short-term assets ($659.38M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RDUS's short-term assets ($659.38M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RDUS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
RDUS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$21.2M
Investing
-$19.0M
Financing
$33.2M
RDUS's operating cash flow ($184.20M)... subscribe to Premium to read more.
Debt Coverage Financials
RDUS vs Steel Stocks
Radius Recycling Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.